After the phase 3 results (Allegro and Bravo studies) Teva's CEO Shlomo Yanai made the following statement concerning laquinimod:
"It is clear from these results and the CEO's statement that Teva will need to do more clinical trials to get laquinimod licensed."
"I am of the opinion that Teva should have tested a large dose of laquinimod in the phase 3 program; hindsight is easy. A very expensive mistake? Hopefully, Teva will now pursue the program with a larger dose or possibly as an add-on to other drugs in separate studies."